公开(公告)号：US12232949B2

公开(公告)日：2025-02-25

申请号：US16080852

申请日：2017-02-28

Applicant: Cedars-Sinai Medical Center

Inventor： Dan Gazit ,  Gadi Pelled ,  Thomas Kremen

IPC: A61F2/08 ,  A61K38/18 ,  A61L27/24 ,  A61L27/54

Abstract: Tendon and ligament injuries are common in orthopaedic clinical practice and cause substantial morbidity in sports and in routine daily activities. While surgical reconstruction is effective, the majority of patients suffer from a prolonged period of recovery because of limited regeneration capacity of the tendon-bone interface. Here, the Inventors have established an approach for promoting tendon/ligament integration. By first recruiting endogenous stem cells to the site of injury, bone morphogenic proteins (BMPs), are then delivered in vivo to promote repair. Significant acceleration of healing via the above methods and compositions leads to fast recovery and return to normal activities, thereby providing new therapeutic avenues for treatment of injuries involving the tendon-bone interface.

公开(公告)号：US12226452B2

公开(公告)日：2025-02-18

申请号：US17192328

申请日：2021-03-04

Applicant: The Schepens Eye Research Institute, Inc. ,  Cell Guidance Systems Ltd

Inventor： Julia Oswald Clifton ,  Christian Pernstich ,  Petr Baranov ,  Michael Jones

IPC: A61K38/18 ,  A61P27/06

Abstract: Described herein are polyhedrin-based slow release growth factor systems and methods of use thereof for neuroprotection of host and donor retinal ganglion cell neurons.

公开(公告)号：US20250042959A1

公开(公告)日：2025-02-06

申请号：US18800870

申请日：2024-08-12

Applicant: VANDERBILT UNIVERSITY ,  The United States as Represented by The Department of Veterans Affairs

Inventor： Ambra A. POZZI ,  Manuel CHIUSA ,  Jack J. HAWIGER ,  Jozef ZIENKIEWICZ

IPC: C07K14/47 ,  A61K38/17 ,  A61K38/18 ,  A61K45/06 ,  A61P13/12 ,  C07K14/50 ,  C07K14/705

Abstract: Disclosed herein are compositions and methods for inhibiting collagen production mediated by the Fused in Sarcoma (FUS) ribonucleoprotein. As disclosed herein, the C terminal domain of FUS contains an uncommon nuclear localization sequence (NLS) motif called PY-NLS that binds the nuclear import receptor transportin. Phosphorylation of FUS leads to its association with transportin and nuclear translocation with consequent increased in collagen production. Therefore, disclosed herein is an isolated peptide having a transportin-binding moiety, which inhibits FUS from binding transportin, linked to a membrane translocating motif. These compositions and methods can be used to inhibit FUS-mediated collagen production, and treat fibrotic disease involving FUS-mediated collagen accumulation in kidneys and other organs displaying fibrotic diseases.

公开(公告)号：US20250032581A1

公开(公告)日：2025-01-30

申请号：US18552266

申请日：2022-03-25

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Illana GOZES

IPC: A61K38/18 ,  C07K14/475

Abstract: Compositions and articles comprising an ADNF polypeptide are provided. Accordingly, there is provided an article of manufacture comprising as active ingredients an ADNF polypeptide and a SIRT1 activator. Also provided are methods of treating a disease that can benefit from the article of manufacture.

公开(公告)号：US12208168B2

公开(公告)日：2025-01-28

申请号：US18308810

申请日：2023-04-28

Applicant: UNIVERSITY OF SOUTH CAROLINA

Inventor： Esmaiel Jabbari

IPC: A61K38/00 ,  A61K9/51 ,  A61K47/65 ,  C07K7/00 ,  A61K38/18

Abstract: The present disclosure is directed to hybrid multifunctional macromers that can self-assemble to form nanoparticles for on-demand and targeted release of morphogens. Embodiments of the disclosure can include the hybrid multifunctional macromers and peptide sequences incorporated therein, self-assembled nanoparticles including the hybrid multifunctional macromers, methods for producing the hybrid multifunctional macromers and peptide sequences, and methods for treating a disease by the on-demand and targeted delivery of a compound using the hybrid multifunctional macromers.

公开(公告)号：US12201757B2

公开(公告)日：2025-01-21

申请号：US17611782

申请日：2020-05-22

Applicant: KNOW Bio, LLC

Inventor： Nicholas William Medendorp, Jr. ,  Katelyn Reighard Crizer

IPC: A61N5/06 ,  A61K35/16 ,  A61K38/18 ,  A61M1/02

Abstract: Embodiments provide methods and apparatus for fabricating blood products, such as platelet-rich plasma, containing elevated concentrations of growth factors such as platelet derived growth factor. The platelet-rich plasma can be autologous, and the concentration of growth factors (e.g., platelet derived growth factor) is elevated relative to other samples isolated from the same subject. The platelet-rich plasma can be used to promote tissue regeneration, including wound healing, joint repair, hair growth, and the like. The compositions can be combined with stem cells and used to treat disorders otherwise treated with stem cells. The growth factors present in the samples can direct the differentiation of the stem cells.

公开(公告)号：US20250009846A1

公开(公告)日：2025-01-09

申请号：US18686041

申请日：2022-08-24

Applicant: SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE ,  SHANGHAI RNACURE BIOPHARMA CO., LTD.

Inventor： Yingjie XU ,  Xiang YU ,  Wei XU ,  Wen YANG ,  Zheng YANG ,  Yu ZHANG

IPC: A61K38/18 ,  A61K9/127 ,  A61P25/02 ,  C07K14/48

Abstract: Provided is a recombinant protein, which contains a nerve growth factor (NGF) protein variant and a heterologous signal peptide linked to the NGF protein variant. Further provided are a combination containing an mRNA encoding the recombinant protein and a delivery vector, and the use thereof in the treatment of toxic/hereditary/metabolic peripheral neuropathy, nerve regeneration repair, and/or central nervous system degenerative diseases.

公开(公告)号：US12186413B2

公开(公告)日：2025-01-07

申请号：US17441611

申请日：2020-03-27

Applicant: KOWA COMPANY, LTD.

Inventor： Misako Nakashima ,  Koichiro Iohara

IPC: A61K6/54 ,  A61K6/69 ,  A61K6/80 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/4725 ,  A61K38/18 ,  A61K38/19 ,  A61K38/48 ,  A61K45/06 ,  A61L27/22 ,  A61L27/36 ,  A61L27/54 ,  A61P1/02

Abstract: A non-cellular root canal filler comprises a tetrahydroisoquinoline compound or a pharmaceutically acceptable salt thereof, or a solvate of the compound or the salt, and a dental tissue regeneration promotion kit comprises a pretreatment agent comprising a serine protease, and the non-cellular root canal filler.

公开(公告)号：US20240424060A1

公开(公告)日：2024-12-26

申请号：US18763519

申请日：2024-07-03

Applicant: DOMPE' FARMACEUTICI SPA

Inventor： Andrea ARAMINI ,  Pier Giorgio AMENDOLA ,  Anna SIRICO ,  Gaetano D'ANNIBALLE ,  Franca CATTANI ,  Marcello ALLEGRETTI ,  Flavio MANTELLI

IPC: A61K38/18 ,  A61P27/02

Abstract: The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.

公开(公告)号：US12171978B2

公开(公告)日：2024-12-24

申请号：US15470828

申请日：2017-03-27

Applicant: TERUMO KABUSHIKI KAISHA

Inventor： Hideaki Kiminami ,  Koji Nakamura ,  Yoshihiko Abe ,  Shigeru Suzuki ,  Shigeru Tamatsukuri

IPC: A61K38/16 ,  A61J1/00 ,  A61J1/05 ,  A61J1/10 ,  A61J1/14 ,  A61K9/08 ,  A61K38/00 ,  A61K38/18 ,  A61K39/395 ,  A61L2/07 ,  A61M5/00 ,  A61M5/31 ,  B65D75/32

Abstract: A medical container for accommodating a protein solution formulation, in which the medical container is formed from a cycloolefin polymer, sterilized with high-pressure steam, and suppresses oxidization of amino acid residues in a protein in a protein solution formulation accommodated in the medical container.